HIGH ATTENTION
Retatrutide
Strong clinical results are colliding with investigational status.
Human optimization, re-examined
Biohacking
has evolved.
First came supplements. Then wearables. Then optimization. Now biology itself is becoming the frontier.
Peptides, metabolic therapies, mitochondrial science, precision diagnostics and longevity research—separated from hype by evidence.
Performance
Longevity
Biology
Longevity
Biology
01 · Flagship reference
The Peptide Index
A living reference system for understanding human evidence, preclinical research, mechanisms, community attention, regulatory status—and the gap between them.
02 · Outcome Intelligence
Start with the outcome.
Don’t start with a compound. Start with the biology—then compare the strength of evidence behind the molecules being discussed around it.
RecoveryHealing is not one biological process.
Metabolic HealthWeight loss is an outcome. Metabolic health is a system.
Muscle & PerformanceA stronger signal is not the same as a stronger athlete.
LongevityChanging aging biology is not the same as slowing aging.
CognitionFeeling sharper is not proven cognitive enhancement.
Gut Health“Healing the gut” is not one outcome.
SleepSedation is not the same as restorative sleep.
03 · Community Signal
Community Pulse.
What people are talking about, trying and reporting right now—kept deliberately separate from clinical evidence.
SUSTAINED HIGH
BPC-157
Recovery enthusiasm remains far ahead of controlled human evidence.
RISING INTEREST
KPV
Gut and inflammation narratives are moving faster than human validation.
04 · Living intelligence
What Changed?
Research. Regulatory. Market. The developments that materially change how a compound should be understood.
Latest Update · October 2026
Retatrutide’s Phase 3 evidence just got stronger.
Peer-reviewed Phase 3 data strengthen the efficacy story—and move dysesthesia and hypotension from emerging observations into controlled clinical-trial safety signals.
Science · Controlled human evidence · See what changed →NEW RESEARCH · PRECLINICAL
GHK-Cu
A new diabetic-wound hydrogel study expands the regenerative research story without changing the limits of injectable human evidence.
EDITOR’S RADAR · PHASE 2
EloraTZP
Lilly’s experimental amylin + GIP/GLP-1 combination joins the watchlist after a striking early efficacy signal.
05 · Editor’s Radar
Where the story is moving fastest.
The compounds where science, community momentum, regulation and market activity are changing fastest.
#1 · Market + Research
Retatrutide
Peer-reviewed Phase 3 publications, exceptional weight-loss efficacy, new safety detail and investigational status are converging around one molecule.
#2 · The Gap
BPC-157
Few compounds better demonstrate the distance between online adoption and clinical validation.
#3 · Next-generation metabolic
EloraTZP
An experimental amylin + GIP/GLP-1 combination is showing an early efficacy signal strong enough to watch—alongside a meaningful tolerability question.
06 · Decision tool
Compare the signals.
One compound can tell several different stories at once. Put two side by side across human evidence, preclinical depth, regulatory status and community momentum.
VS.
07 · The Evolution
Biohacking didn’t begin with peptides—and it won’t end with them.
From supplements and quantified self to wearables, longevity medicine, GLP-1s, peptides and mitochondrial therapeutics, the definition of human optimization keeps changing.
THE EVOLUTION
How did we get here?
WHAT’S NEXT
Where is human optimization going?
Follow the technologies and therapeutic directions moving beyond today’s peptide conversation.
Explore What’s Next →